CPT code 81372 denotes a laboratory-based molecular test for low- or intermediate-resolution typing of human leukocyte antigen (HLA) Class I loci — specifically HLA–A, HLA–B, and HLA–C. This code matters nationally because HLA Class I typing is central to organ and stem cell transplant compatibility assessment, donor matching, and certain immunogenetic evaluations that affect patient safety and transplant outcomes. Accurate coding supports appropriate lab workflows, payer adjudication, and clinical decision-making.

Key payers analyzed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical intent and service setting for the code, a summary of common billing modifiers used with molecular laboratory services, and indicators of where CPT code 81372 fits among related HLA and molecular testing services. The publication outlines typical sites of service and operational considerations relevant to laboratories and billing teams.

This briefing is designed to inform laboratory administrators, coding and billing professionals, and clinicians about the clinical context and administrative handling of CPT code 81372, provide benchmarking context where available, and highlight policy and coding considerations affecting national reimbursement practices. Data not available in the input will be noted where applicable.